Stability of the novel blood‐based biomarkers under pre‐analytical sample handling conditions: Results of the SABB‐GBSC working group. (31st December 2021)
- Record Type:
- Journal Article
- Title:
- Stability of the novel blood‐based biomarkers under pre‐analytical sample handling conditions: Results of the SABB‐GBSC working group. (31st December 2021)
- Main Title:
- Stability of the novel blood‐based biomarkers under pre‐analytical sample handling conditions: Results of the SABB‐GBSC working group
- Authors:
- Verberk, Inge M.W.
Misdorp, Els O.
Koelewijn, Jannet
Ball, Andrew J.
Blennow, Kaj
Dage, Jeffrey L.
Fandos, Noelia
Hansson, Oskar
Hirtz, Christophe
Janelidze, Shorena
Lee, Ryan
Rissman, Robert A.
Shan, Dandan
Shaw, Leslie M.
Yarasheski, Kevin E.
Zetterberg, Henrik
Edelmayer, Rebecca M.
Teunissen, Charlotte E. - Abstract:
- Abstract: Background: Pre‐analytical sample handling might affect the results of Alzheimer's blood‐based biomarkers. In this collaborative study of the SABB‐GBSC working group guided by the Alzheimer's Association, we elucidate the effects of the most common sample handling variations on blood‐based amyloid and non‐amyloid biomarkers. Method: Freshly collected blood was differentially treated, to create sample sets (n=10 per condition). We investigated the effect of collection tube type, and of EDTA plasma handling variations: delayed centrifugation, centrifugation temperature, aliquot volume, delayed storage, and freeze‐thawing. Frozen aliquots were shipped to participating labs, to measure amyloid beta (Abeta) peptides (with different technologies: C2 N LS‐mass spectrometry (MS), Shimadzu MALID‐MS, N4PE and N3PA Simoa, Euroimmun and Araclon ELISA), Abeta oligomerization tendency (OAβ; PeopleBio), glial fibrillary acidic protein (GFAP; Quanterix), neurofilament light (NfL; Quanterix), total tau (tTau; Quanterix) and phosphorylated tau181 (pTau181; Eli Lilly Simoa assay). Data analysis was descriptive. Result: Using other sample types than EDTA plasma resulted in different absolute levels for most of the measured biomarkers (figures 1‐4), with generally higher levels in lithium‐heparin plasma, lower levels in sodium‐citrate plasma, and variable but comparable levels in serum. Independent of the technology used, when EDTA plasma was kept at room temperature pre‐ orAbstract: Background: Pre‐analytical sample handling might affect the results of Alzheimer's blood‐based biomarkers. In this collaborative study of the SABB‐GBSC working group guided by the Alzheimer's Association, we elucidate the effects of the most common sample handling variations on blood‐based amyloid and non‐amyloid biomarkers. Method: Freshly collected blood was differentially treated, to create sample sets (n=10 per condition). We investigated the effect of collection tube type, and of EDTA plasma handling variations: delayed centrifugation, centrifugation temperature, aliquot volume, delayed storage, and freeze‐thawing. Frozen aliquots were shipped to participating labs, to measure amyloid beta (Abeta) peptides (with different technologies: C2 N LS‐mass spectrometry (MS), Shimadzu MALID‐MS, N4PE and N3PA Simoa, Euroimmun and Araclon ELISA), Abeta oligomerization tendency (OAβ; PeopleBio), glial fibrillary acidic protein (GFAP; Quanterix), neurofilament light (NfL; Quanterix), total tau (tTau; Quanterix) and phosphorylated tau181 (pTau181; Eli Lilly Simoa assay). Data analysis was descriptive. Result: Using other sample types than EDTA plasma resulted in different absolute levels for most of the measured biomarkers (figures 1‐4), with generally higher levels in lithium‐heparin plasma, lower levels in sodium‐citrate plasma, and variable but comparable levels in serum. Independent of the technology used, when EDTA plasma was kept at room temperature pre‐ or post‐centrifugation, Abeta42 and Abeta40 levels remained stable for up to 3 hours, while at 24 hours levels were decreased. When kept at 2‐8°C, Abeta levels were stable for up to 24 hours delayed centrifugation or storage (figure 1 and 2). The Abeta42/40 ratio mitigated some of the variability noted in Abeta42 and Abeta40 levels for some of the technologies and conditions, but not for all (figure 3). Abeta42 and Abeta40 levels were robust to differences in tube filling, short‐term ‐20°C storage, and up to 4 freeze‐thaw cycles (figure 1 and 2). While the other biomarkers OAβ, GFAP, NfL and pTau181 were mostly resistant to pre‐analytical sample handling variations, tTau levels were affected by delayed centrifugation and by centrifugation temperature (figure 4). Conclusion: Based on the current findings, we construct a standardized operating procedure for pre‐analytical blood sample handling, that will facilitate swift introduction of blood‐based biomarkers into research and clinical settings. … (more)
- Is Part Of:
- Alzheimer's & dementia. Volume 17(2021)Supplement 5
- Journal:
- Alzheimer's & dementia
- Issue:
- Volume 17(2021)Supplement 5
- Issue Display:
- Volume 17, Issue 5 (2021)
- Year:
- 2021
- Volume:
- 17
- Issue:
- 5
- Issue Sort Value:
- 2021-0017-0005-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2021-12-31
- Subjects:
- Alzheimer's disease -- Periodicals
Alzheimer Disease -- Periodicals
Dementia -- Periodicals
Démence
Maladie d'Alzheimer
Périodique électronique (Descripteur de forme)
Ressource Internet (Descripteur de forme)
616.83 - Journal URLs:
- http://www.sciencedirect.com/science/journal/15525260 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1002/alz.055441 ↗
- Languages:
- English
- ISSNs:
- 1552-5260
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0806.255333
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25828.xml